T cell receptor peptide vaccines: CNCT plans Phase I/II trial

Connective Therapeutics Inc. (CNCT), Palo Alto, Calif. Product: ConXn recombinant human relaxin H2 Indication: Scleroderma Status: Enrollment of 60 patients has been completed in the Phase II trial ...